Avacta’s AffiDX SARS-CoV-2 Antigen Lateral Flow Test detects Delta variant with high sensitivity
Avacta Group, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, says a recent study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples. Lateral flow antigen tests are intended to provide a cost effective and rapid means […]